Kringle Pharma (TSE:4884) Research & Development: 円0.00 Mil (TTM As of Mar. 2026)


TSE:4884 Kringle Pharma Inc TSE:4884
45 GF Score
Price 円318.00
GF Value 円497.82
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Kringle Pharma Research & Development?

Kringle Pharma TSE:4884 +2.91% 45 Research & Development is 円0.00 Mil as of Mar. 2026. GuruFocus rates TSE:4884 with a GF Score™ of 45/100 and a GF Value™ of 円497.82 (Possible Value Trap). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Kringle Pharma's Research & Development for the three months ended in Mar. 2026 was 円0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was 円0.00 Mil.

Kringle Pharma  (TSE:4884) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Kringle Pharma Research & Development Related Terms

Kringle Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for Kringle Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kringle Pharma Research & Development Chart

Kringle Pharma Annual Data
Trend Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Kringle Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4884
45GF Score
Kringle Pharma Inc TSE:4884
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kringle Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円0.00 Mil mean?
Kringle Pharma (TSE:4884) has a Research & Development of 円0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Kringle Pharma and its competitors.
Is Kringle Pharma's Research & Development too high?
Kringle Pharma's current Research & Development is 円0.00 Mil. Overall, Kringle Pharma has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's Research & Development compare to VRTX and REGN?
Kringle Pharma's Research & Development of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Kringle Pharma and its competitors. Kringle Pharma's current Research & Development is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Possible Value Trap. The stock's GF Value™ is 円497.82, compared to a current price of 円318.00 — trading 36.1% below its estimated fair value. The current Research & Development is 円0.00 Mil. Kringle Pharma's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current Research & Development is 円0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kringle Pharma (TSE:4884) Overvalued in 2026?

Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued. The current stock price of 円318.00 is trading 36.1% below its estimated GF Value™ of 円497.82. GuruFocus considers Kringle Pharma to be Possible Value Trap.

Key valuation signals for TSE:4884:

  • Research & Development: 円0.00 Mil
  • GF Value™: 円497.82 vs. price of 円318.00 (36.1% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kringle Pharma Business Description

Address 7-7-15 Saito asagi, 207 Saito Bio-Incubator, Osaka Prefecture, Ibaraki, JPN, 567-0085
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
45GF Score

Get the complete analysis for TSE:4884

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円318.00
Price
円497.82
GF Value